Remission in Ketosis-Prone Diabetes
-
Nupur Kikani [1] ; Ashok Balasubramanyam [2]
-
[1] University of Texas MD Anderson Cancer Center
University of Texas MD Anderson Cancer Center
Estados Unidos
-
[2] Division of Diabetes, Endocrinology, and Metabolism, Baylor College of Medicine, BCM 179A, One Baylor Plaza, Houston, TX 77030, USA
-
- Localización: Endocrinology and metabolism clinics of North America, ISSN 0889-8529, Vol. 52, Nº. 1, 2023, págs. 165-174
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
Heterogeneous forms of Ketosis-prone diabetes (KPD) are characterized by patients who present with diabetic ketoacidosis (DKA) but lack the typical features and biomarkers of autoimmune T1D. The A-β+ subgroup of KPD provides unique insight into the concept of "remission" since these patients have substantial preservation of beta-cell function permitting the discontinuation of insulin therapy, despite initial presentation with DKA. Measurements of C-peptide levels are essential to predict remission and guide potential insulin withdrawal. Further studies into predictors of remission and relapse can help us guide patients with A-β+ KPD toward remission and develop targeted treatments for this form of atypical diabetes.
